Ultrasound contrast agent developer Molecular Biosystems has completed phase II clinical trials of its Oralex oral ultrasound contrast agent, which is targeted for the improvement of abdominal ultrasound images. Preliminary data evaluation of the
Ultrasound contrast agent developer Molecular Biosystems has completed phase II clinical trials of its Oralex oral ultrasound contrast agent, which is targeted for the improvement of abdominal ultrasound images. Preliminary data evaluation of the 59-patient study found that Oralex provided significant diagnostic utility when compared with noncontrast and water-contrast imaging, according to MBI.
Oralex works by distending the stomach and displacing bowel gas to provide physicians with a better view of the upper gastrointestinal anatomy, including the stomach wall and pancreas. The San Diego-based firm believes that Oralex provides significant benefit over the current method of improving ultrasound images, which involves ingestion of water.
What a New Study Reveals About Adjunctive DBT and Early-Stage Invasive Breast Cancer
December 6th 2023The combination of digital breast tomosynthesis (DBT) and digital mammography had a 21.6 higher invasive breast cancer detection rate for stage 1 tumors than digital mammography alone, according to a new study involving nearly 100,000 women.